<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900413-0044</DOCNO><DOCID>900413-0044.</DOCID><HL>   Business Brief -- Par Pharmaceutical Inc.:   Accord Set on Quad Unit;   Managers to Sell 40% Stake</HL><DATE>04/13/90</DATE><SO>WALL STREET JOURNAL (J), PAGE C8</SO><CO>   PRX</CO><IN>TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><LP>   Par Pharmaceutical Inc. said it reached agreement with itsmajority-owned subsidiary, Quad Pharmaceuticals Inc., to buyout Quad management's 40% interest in the unit.   Terms weren't disclosed.</LP><TEXT>   Par, a Spring Valley, N.Y., genericdrug manufacturer underfederal investigation, said the transaction, which is subjectto a definitive agreement and approval by boards of bothcompanies, would result in Quad being wholly owned by Par.   In addition, Par said senior managers atIndianapolis-based Quad, who are now on leaves of absence,would resign once the transaction closes. Quad is currentlybeing operated by Par management.   Officials of both companies couldn't be reached forcomment.   In late March, Par said Quad had halted distribution ofall products subject to federal approval. That action, whichconcerned findings the company might have made productchanges without following appropriate regulatory notificationor approval processes, came after Quad had recalled otherproducts.</TEXT></DOC>